Forte Biosciences, Inc.
FBRX
$12.65
-$1.01-7.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.00% | -12.71% | -12.18% | -49.45% | -77.93% |
| Total Depreciation and Amortization | 138.89% | 333.33% | 1,066.67% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.41% | -6.85% | -1.27% | -12.63% | -19.86% |
| Change in Net Operating Assets | 611.17% | 548.21% | -72.51% | -58.23% | -139.77% |
| Cash from Operations | -14.13% | -7.10% | -31.26% | -97.46% | -164.32% |
| Capital Expenditure | 2.13% | 57.95% | 67.61% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 191.85% | -26,734.07% | -99.25% | 201.35% | -- |
| Cash from Investing | 636.59% | -76,680.85% | -134.92% | 200.41% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 111.91% | 111.92% | -99.10% | 243.18% | 243.18% |
| Repurchase of Common Stock | 55.26% | 41.67% | 56.31% | 21.52% | -38.18% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,163.97% | -312.50% | -- | -274.36% | -691.30% |
| Cash from Financing | 100.82% | 110.08% | -100.38% | 235.06% | 238.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 382.37% | -274.36% | -1,495.51% | 122.42% | -32.06% |